Literature DB >> 16850492

The high post-test probability of a cytological examination renders further investigations to establish a diagnosis of epithelial malignant pleural mesothelioma redundant.

J G J V Aerts1, M Delahaye, T H van der Kwast, B Davidson, H C Hoogsteden, J P van Meerbeeck.   

Abstract

The aim of the study was to establish in a prospective and blinded manner the diagnostic yield of morphology, immunocytochemistry (ICH) and electron microscopy (EM) in the cytological analysis of malignant pleural mesothelioma (MPM). Pleural fluid from consecutive patients, 14 with a histologically proven MPM, 12 with a malignant pleuritis due to adenocarcinoma (AC), and 13 with a reactive pleural effusion (RM), was separately analyzed. Smears were incubated with monoclonal antibodies (Tag72, Ber-Ep4, anti-CEA, EMA). These were considered suggestive for MPM when only EMA stained positive, for AC when three out of four markers stained positive, and for RM when no marker stained positive. The post-test probability of the morphological, ICH, and EM analysis were 92, 100, 92% or MPM, 91, 100, 86% for AC, and 88, 88, 90% for RM, respectively. We concluded that the high post-test probability of a combined morphological and ICH diagnosis of MPM warrants to cease further diagnostic procedures in these patients. Electron microscopy did not add to accuracy of diagnosis. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2006        PMID: 16850492     DOI: 10.1002/dc.20486

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  7 in total

Review 1.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

2.  BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.

Authors:  Marta Cigognetti; Silvia Lonardi; Simona Fisogni; Piera Balzarini; Vilma Pellegrini; Andrea Tironi; Luisa Bercich; Mattia Bugatti; Giulio Rossi; Bruno Murer; Mattia Barbareschi; Silvia Giuliani; Alberto Cavazza; Gianpietro Marchetti; William Vermi; Fabio Facchetti
Journal:  Mod Pathol       Date:  2015-05-29       Impact factor: 7.842

3.  Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA.

Authors:  Rosa Filiberti; Stefano Parodi; Roberta Libener; Giovanni Paolo Ivaldi; Pier Aldo Canessa; Donatella Ugolini; Barbara Bobbio; Paola Marroni
Journal:  Med Oncol       Date:  2013-03-27       Impact factor: 3.064

4.  Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions.

Authors:  Fabio Facchetti; Silvia Lonardi; Francesca Gentili; Luisa Bercich; Marcella Falchetti; Regina Tardanico; Carla Baronchelli; Laura Lucini; Alessandro Santin; Bruno Murer
Journal:  Virchows Arch       Date:  2007-07-03       Impact factor: 4.064

5.  Endoscopic ultrasound fine needle aspiration in the diagnosis of lymphoma.

Authors:  Koen Creemers; Olaf van der Heiden; Jan Los; Joost van Esser; David Newhall; Remco S Djamin; Joachim G Aerts
Journal:  J Oncol       Date:  2011-04-10       Impact factor: 4.375

6.  Differential diagnosis of pleural mesothelioma using Logic Learning Machine.

Authors:  Stefano Parodi; Rosa Filiberti; Paola Marroni; Roberta Libener; Giovanni Paolo Ivaldi; Michele Mussap; Enrico Ferrari; Chiara Manneschi; Erika Montani; Marco Muselli
Journal:  BMC Bioinformatics       Date:  2015-06-01       Impact factor: 3.169

7.  Diagnostic accuracy of Ber-EP4 for metastatic adenocarcinoma in serous effusions: a meta-analysis.

Authors:  Bo Wang; Diandian Li; Xuemei Ou; Qun Yi; Yulin Feng
Journal:  PLoS One       Date:  2014-09-17       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.